Your Health, We Care

Home > Photo Wall > Honor and qualification

Approval for Lenvatinib 4mg

Release date: 2024-07-09 16:29:30     Recommended: 116

03L1079_24 乐伐替尼4mg 批文_00.jpg

Lenvatinib is suitable for unresectable hepatocellular carcinoma patients who have not received systemic treatment in the past. The key study of lenvatinib mesylate excluded liver cancer patients who could receive local treatment, and there is no available research data for such patients. Patients with progressive, locally advanced, or metastatic radioactive iodine refractory differentiated thyroid cancer.

Company News

Research News

Drug news